Mulmit

CHAMPIONS ONCOLOGY, INC.CHAMPIONS ONCOLOGY, INC.

CSBR Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2026-04-3059,425,000-1,140,000-1,175-0.08
2025-04-3056,944,0004,553,0004,7010.33
2024-04-3050,155,000-7,356,000-7,276-0.54
2023-04-3053,870,000-5,256,000-5,335,000-0.39
2022-04-3049,109,000607,000548,0000.04

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2025-11-05Breitfeld Philip P.13,790
2025-11-05SIDRANSKY DAVID21,216
2025-11-05Mendelson Daniel Newman13,790
2025-11-05TOBIN SCOTT R25,460
2025-11-05ACKERMAN JOEL21,216
2025-10-30ACKERMAN JOEL94,405
2025-10-30ACKERMAN JOEL94,405
2025-07-16Brainin Robert LawrenceCEO225,000
2025-07-16Brainin Robert LawrenceCEO62,500
2025-07-16Brainin Robert LawrenceCEO62,500
2025-07-16Brainin Robert LawrenceCEO150,000
2025-07-16Brainin Robert LawrenceCEO100,000

8-K events

FiledItems
2026-07-27Results of operations · Financial statements and exhibits
2026-03-30Officer or director change · Financial statements and exhibits
2026-03-12Results of operations · Financial statements and exhibits
2025-12-15Results of operations · Financial statements and exhibits
2025-10-16Submission of matters to a vote
2025-09-15Results of operations · Financial statements and exhibits
2025-07-23Results of operations · Financial statements and exhibits
2025-07-21Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

Biological Products, (No Diagnostic Substances) — 같은 업종, 그리고 규모가 비슷한 기업Biological Products, (No Diagnostic Substances) — and other companies of a similar size

SEC가 같은 업종(Biological Products, (No Diagnostic Substances))으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (Biological Products, (No Diagnostic Substances)) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.